Skip to Content
Merck
  • HIV-1 and its gp120 inhibits the influenza A(H1N1)pdm09 life cycle in an IFITM3-dependent fashion.

HIV-1 and its gp120 inhibits the influenza A(H1N1)pdm09 life cycle in an IFITM3-dependent fashion.

PloS one (2014-07-01)
Milene Mesquita, Natalia Fintelman-Rodrigues, Carolina Q Sacramento, Juliana L Abrantes, Eduardo Costa, Jairo R Temerozo, Marilda M Siqueira, Dumith Chequer Bou-Habib, Thiago Moreno L Souza
ABSTRACT

HIV-1-infected patients co-infected with A(H1N1)pdm09 surprisingly presented benign clinical outcome. The knowledge that HIV-1 changes the host homeostatic equilibrium, which may favor the patient resistance to some co-pathogens, prompted us to investigate whether HIV-1 infection could influence A(H1N1)pdm09 life cycle in vitro. We show here that exposure of A(H1N1)pdm09-infected epithelial cells to HIV-1 viral particles or its gp120 enhanced by 25% the IFITM3 content, resulting in a decrease in influenza replication. This event was dependent on toll-like receptor 2 and 4. Moreover, knockdown of IFITM3 prevented HIV-1 ability to inhibit A(H1N1)pdm09 replication. HIV-1 infection also increased IFITM3 levels in human primary macrophages by almost 100%. Consequently, the arrival of influenza ribonucleoproteins (RNPs) to nucleus of macrophages was inhibited, as evaluated by different approaches. Reduction of influenza RNPs entry into the nucleus tolled A(H1N1)pdm09 life cycle in macrophages earlier than usual, limiting influenza's ability to induce TNF-α. As judged by analysis of the influenza hemagglutin (HA) gene from in vitro experiments and from samples of HIV-1/A(H1N1)pdm09 co-infected individuals, the HIV-1-induced reduction of influenza replication resulted in delayed viral evolution. Our results may provide insights on the mechanisms that may have attenuated the clinical course of Influenza in HIV-1/A(H1N1)pdm09 co-infected patients during the recent influenza form 2009/2010.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
MISSION® esiRNA, targeting mouse Ifitm3
Sigma-Aldrich
1,4-Diazabicyclo[2.2.2]octane, ReagentPlus®, ≥99%
Sigma-Aldrich
Dabco® 33-LV
Sigma-Aldrich
p-Phenylenediamine, ≥99.0% (GC/NT)
Sigma-Aldrich
p-Phenylenediamine, 98% (GC)
Sigma-Aldrich
Glycerol solution, 83.5-89.5% (T)
Sigma-Aldrich
p-Phenylenediamine, sublimed, ≥99%
Supelco
Propyl gallate, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
MISSION® esiRNA, targeting human IFITM3
Sigma-Aldrich
Propyl gallate, ≥98%, FCC
Sigma-Aldrich
Propyl gallate, for microscopy, ≥98.0% (HPLC)
Sigma-Aldrich
Propyl gallate, antioxidant, ≥98.0% (HPLC)
Sigma-Aldrich
Propyl gallate, powder
Sigma-Aldrich
Glycerol, ACS reagent, ≥99.5%
USP
Glycerin, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Glycerol, ReagentPlus®, ≥99.0% (GC)
Sigma-Aldrich
Glycerol, ≥99.5%
Sigma-Aldrich
Glycerol, FCC, FG
Sigma-Aldrich
Glycerol, BioUltra, for molecular biology, anhydrous, ≥99.5% (GC)
Sigma-Aldrich
Glycerol, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for electrophoresis, ≥99% (GC)
Sigma-Aldrich
Glycerol, for molecular biology, ≥99.0%
Supelco
Glycerin, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Glycerol, tested according to Ph. Eur., anhydrous
Sigma-Aldrich
Glycerin, meets USP testing specifications
Sigma-Aldrich
Glycerol, BioXtra, ≥99% (GC)
Supelco
Glycerol, analytical standard
USP
Propyl gallate, United States Pharmacopeia (USP) Reference Standard